deltatrials
Completed PHASE2 NCT00001959

Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)

Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II Study

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions Fibrosis Focal Glomerulosclerosis Kidney Failure Nephrotic Syndrome Proteinuria
Interventions Pirfenidone
Updated 7 times since 2017 Last updated: May 16, 2014 Started: Dec 31, 1999 Primary completion: Oct 31, 2008 Completion: Oct 31, 2008

This PHASE2 trial investigates Fibrosis and Focal Glomerulosclerosis and is currently completed. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) leads this study, which shows 7 recorded versions since 1999 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Dec 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States